(Q36615385)

English

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study

scientific article published on October 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

V Georgoulias

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A Agelidou

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

K Syrigos

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A Rapti

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Agelidou

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J Nikolakopoulos

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A Polyzos

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A Athanasiadis

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

E Tselepatiotis

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

N Androulakis

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

K Kalbakis

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

G Samonis

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

D Mavroudis

13

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

93

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

763-769

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

EQ-5D: a measure of health status from the EuroQol Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Where to go with new expensive treatments in NSCLC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Multimodality management of regionally advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

30 September 2017

Management strategies for recurrent non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

28 June 2018

Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

28 June 2018

Effects of CPT-11 in combination with other anti-cancer agents in culture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

28 June 2018

Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

28 June 2018

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

20 September 2018

Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

20 September 2018

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

20 September 2018

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

20 September 2018

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

20 September 2018

Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361638

20 September 2018

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16175189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16175189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single agents in the second-line treatment of non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16175189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16175189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival-rate estimation in a randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16175189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin

1 reference

https://pubmed.ncbi.nlm.nih.gov/16175189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16175189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6602748

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36615385&oldid=2199093723"